Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.44 |
| ▸ | NPC1 | O15118 | 8/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.44 |
| ▸ | MAPT | P10636 | 7/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.39 |
| ▸ | TP53 | P04637 | 4/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 4/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3542473 | 0.86 | RAB9A (0.44) | RAB9ANPC1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL13314762 | 0.86 | RAB9A (0.44) | RAB9ANPC1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL3536924 | 0.82 | RAB9A (0.46) | RAB9ANPC1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL3540501 | 0.81 | RAB9A (0.67) | RAB9ANPC1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL13314769 | 0.81 | RAB9A (0.67) | RAB9ANPC1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL13314763 | 0.77 | MAPT (0.57) | RAB9ANPC1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL3537545 | 0.77 | PDK1 (0.56) | RAB9ANPC1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL13314760 | 0.77 | RAB9A (0.46) | RAB9ANPC1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL3536479 | 0.77 | MAPT (0.57) | RAB9ANPC1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL3539167 | 0.77 | RAB9A (0.46) | RAB9ANPC1SMN1; SMN2MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7524871-B2 | Thrombin inhibitors | UNIVERSITY OF LJUBLJANA, FACULTY OF PHARMACY (SI) | 2009-04-28 | — | — | US | disclosed |
| US-7524871-B2 | Thrombin inhibitors | UNIVERSITY OF LJUBLJANA, FACULTY OF PHARMACY (SI) | 2009-04-28 | — | — | US | disclosed |
| US-7524871-B2 | Thrombin inhibitors | UNIVERSITY OF LJUBLJANA, FACULTY OF PHARMACY (SI) | 2009-04-28 | — | — | US | disclosed |
| US-20050165034-A1 | Novel heterocyclic derivatives of tripeptides and tripeptide mimetics; (+-)-2-[3-[(benzylsulfonyl)amino]-6-methyl-2-oxo-1 (2H)-pyridinyl]-N-[(4,5,6,7-tetrahydro-2H-indazole-5-yl]acetamide; anticoagulants | UNIVERSITY OF LJUBLJANA, FACULTY OF PHARMACY (SI) | 2005-07-28 | — | — | US | disclosed |
| EP-1451175-A1 | THROMBIN INHIBITORS | University of Ljubljana (SI) | 2004-09-01 | — | — | EP | disclosed |
| WO-2003048155-A1 | THROMBIN INHIBITORS | UNIVERSITY OF LJUBLJANA (SI) | 2003-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165034-A1 | Novel heterocyclic derivatives of tripeptides and tripeptide mimetics; (+-)-2-[3-[(benzylsulfonyl)amino]-6-methyl-2-oxo-1 (2H)-pyridinyl]-N-[(4,5,6,7-tetrahydro-2H-indazole-5-yl]acetamide; anticoagulants | SERPINC1, TFPI, SERPINE1 | RAB9A 4448/4885NPC1 4758/4885SMN1; SMN2 3394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.